ImmunityBio Inc. IBRX shares are trading lower on Monday. The company announced the resubmission of its supplemental Biologics License Application (sBLA) for ANKTIVA to the FDA. FDA Resubmission The ...
We recently published 10 Big Names With Effortless Double-Digit Gains. ImmunityBio Inc. (NASDAQ:IBRX) was one of the best ...
ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ...
Stocktwits on MSN
IBRX stock declines — ImmunityBio resubmits Anktiva application to FDA with additional data
Following discussions with the FDA beginning in January 2026, ImmunityBio resubmitted its supplemental BLA for papillary-only NMIBC after providing additional data requested by the agency, including ...
Dr. Soon-Shiong joins Nobel laureates, former NIH directors, and leading oncology pioneers in Washington, D.C. to chart a path toward defeating cancer by 2035, with the discussion streamed live at ...
Shares of Culver City-based ImmunityBio Inc. surged yet again late last month to nearly a five-year high as its immunotherapy ...
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best high volume stocks to invest in now. On February 23, ImmunityBio reported exceptional financial growth for 2025, headlined by a 700% year-over-year ...
We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Tuesday. ImmunityBio extended its winning streak ...
Shares of ImmunityBio, Inc. IBRX soared 41.9% on Wednesday after the company announced that the European Commission (EC) has granted conditional marketing authorization for Anktiva (nogapendekin alfa ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX) (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted ...
Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results